Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

NCT06531824 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06531824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06531824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 30, 2024
Completion date
December 31, 2026
Enrollment
8,371 (actual)
Sites
561

Conditions

As the registry lists them; a condition with its own page is linked.

kidney disease, chronic